About: XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.16 (-5.35%)
XRTXNASDAQXORTX Therapeutics Inc
XORTX Therapeutics Inc share price
XRTX price activity
Last Price
$2.160
Change (24hr)
-0.12 USD (-5.35%)
Volume
14.89K
Volume (4w avg)
-
Open
$2.26
Day Range
$2.15 - $2.31
Previous Close
$2.28
Last Trade
09 Sep, 8:28 pm GMT+0
Delayed
09 Sep, 8:28 pm GMT+0
XRTX price performance
Delayed
09 Sep, 8:28 pm GMT+0
XRTX Market Signals